GPhC review: Pharmacist who issued illegitimate Covid-19 Fit to Fly certificates allowed back under strict conditions

Allegations

This was a principal review hearing following earlier substantive and review proceedings. The case arose from the registrant’s conduct in connection with Covid-19 testing services offered through the pharmacy. The proved allegations were serious and multifaceted. They included the placing of a used Covid-19 swab back into its packaging, failures to keep records of tests and courier services, the issuing of Fit to Fly certificates that purported to confirm negative rapid antigen results from Circular 1 Health, the acceptance of cash-only payments for Covid-19 tests, and recording that money as “no sale”. The case also included findings that the registrant knew the tests were not, or would not be, processed by Circular 1 Health and knew the certificates issued to patients were not legitimate. Added to that were findings around the use of a Fit2Fly 24/7 swab kit, statements to a GPhC inspector about which provider was being used, a dishonest email saying UKAS accreditation had been applied for when it had not, and a broader failure over approximately a year to ensure the testing service was UKAS accredited or to make the relevant application. In practical pharmacy terms, this was not a narrow record-keeping lapse: it was a case about the integrity of a clinical and public-health-facing service, the reliability of governance systems, and the legitimacy of documentation given to members of the public for travel and reassurance purposes.

For pharmacists, the procedural significance is obvious. Covid-19 testing services during that period depended on clear chain-of-custody processes, accurate documentation, use of authorised pathways, proper engagement with laboratory or testing partners, and compliance with accreditation requirements. When a pharmacy supplies a testing-related service, especially one connected with a Fit to Fly certificate, the public is entitled to assume that swabs are handled appropriately, courier arrangements are documented, results are genuine, and any certificate reflects a real and verifiable testing process. The committee’s findings show that those assumptions could not safely be made here. That is why the case resonates far beyond the historical context of pandemic services: it is fundamentally about whether a pharmacist can be trusted to run, document and represent a regulated clinical service honestly.